RELATIONSHIPS OF BLOOD-PRESSURE TO FIBRINOLYSIS - INFLUENCE OF ANTHROPOMETRY, METABOLIC PROFILE AND BEHAVIORAL VARIABLES

被引:24
作者
CIGOLINI, M
TARGHER, G
SEIDELL, JC
TONOLI, M
SCHIAVON, R
AGOSTINO, G
DESANDRE, G
机构
[1] UNIV HOSP VERONA, DEPT METAB DIS, I-37134 VERONA, ITALY
[2] UNIV VERONA, INST CLIN CHEM, VERONA, ITALY
[3] RIVM, DEPT CHRON DIS & ENVIRONM EPIDEMIOL, BILTHOVEN, NETHERLANDS
关键词
HYPERTENSION; FIBRINOLYSIS; INSULIN RESISTANCE; ADIPOSE TISSUE FATTY ACIDS;
D O I
10.1097/00004872-199506000-00013
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective: To investigate the relationship between blood pressure and the plasma fibrinolytic system and to verify whether this association was independent or mediated by one or more potential confounding factor. Design: A random sample of 94 males aged 38 years subdivided into normotensives, hypertensives and those hypertensives with the highest blood pressure values. Methods: Overall and regional obesity, blood lipids, fasting and 2-h post-load glucose, C-peptide and insulin levels, and main behavioural variables, including adipose tissue fatty acid composition (an objective index of dietary fat intake), were measured. The plasma fibrinolytic system was evaluated by determining activities and total plasma concentrations of both tissue-type plasminogen activator before and after venous occlusion, and its inhibitor plasminogen activator inhibitor type-1 (PAI-1). Results: PAI-1 activity was significantly higher in the hypertensives than in the normotensives. PAI-1 antigen tended to parallel PAI-1 activity, and levels of tissue-type plasminogen activator antigen and activity tended to be lower in the hypertensives at baseline and after venous occlusion, but not significantly different from those in the normotensives. The hypertensives also had significantly higher body mass index and body fat content (measured by bio-impedance), increased plasma triglycerides, uric acid, fasting and 2-h glucose, C-peptide and insulin concentrations. In univariate linear regression analysis both systolic and diastolic blood pressures were found to be positively correlated with PAI-1 levels (r = 0.27, P< 0.01, for both). This correlation was maintained after adjustment for total body fat, fasting glucose, fasting insulin concentration or adipose tissue alpha-linolenic acid; however, it was no longer significant after adjustment for plasma 2-h insulin, 2-h C-peptide, 2-h glucose or triglyceride levels. Multivariate regression analysis revealed that only 2-h insulin and triglyceride concentration showed an independent association with PAI-1 levels. Conclusions: This study confirms that, in 38-year-old males, hypertension is associated with increased PAI-1 activity. It supports the possibility that the relationship between blood pressure and PAI-1 may reflect the overall effect of the insulin resistance syndrome (in particular hyperinsulinaemia and hypertriglyceridaemia) rather than a direct effect of blood pressure on the fibrinolytic system.
引用
收藏
页码:659 / 666
页数:8
相关论文
共 40 条
  • [1] Bl S., Nilsson T.K., Ranby M., Hallmans C., Hellsten C., Fibrinolytic variables are related to age, sex, blood pressure and body build measurements: A cross-sectional study in Norsjö, Sweden, J Clin Epidemiol, 42, pp. 719-723, (1989)
  • [2] Jansson J.H., Johansson B., Boman K., Nilsson T.K., Hypofibrinolysis in patients with hypertension and elevated Cholesterol, J Intern Med, 229, pp. 309-316, (1991)
  • [3] Landin K., Tengborn I., Smith U., Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease, J Intern Med, 227, pp. 273-278, (1990)
  • [4] Chmielewska J., Wiman B., Determination of tissue plasminogen activator and its fast inhibitor in plasma, Clin Chem, 32, pp. 482-485, (1986)
  • [5] Dawson S., Henney A., The Status of PAI-1 as a risk factor for arterial and thrombotic disease: A review, Atherosclerosis, 95, pp. 105-117, (1992)
  • [6] Hamsten A., de Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., Et al., Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction, Lancet, 2, pp. 3-9, (1987)
  • [7] Guidelines for the management of mild hypertension: Memorandum from a World Health Organization/Intemational Society of Hypertension meeting, Jhypertens, 11, pp. 905-918, (1993)
  • [8] de Fronzo R.A., Ferrannini E., Insulin resistance: A multifaceted syndrome responsible for NID DM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease, Diabetes Care, 14, pp. 173-194, (1991)
  • [9] Daly P.A., Landsberg L., Hypertension in obesity and NIDDM, Diabetes Care, 14, pp. 240-248, (1991)
  • [10] Seidell J.C., Cigolini M., Deslypere J.P., Charzewska J., Ellsinger B.M., Cruz A., Body fat distribution in relation to serum lipids and blood pressure in 38-year-old European men. The European Fat Distribution Study, Atherosclerosis, 86, pp. 251-260, (1991)